Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PROVE A Randomized Phase II Trial of Standard Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer

NCT01388621 is registered in ClinicalTrials.gov with WiSP Wissenschaftlicher Service Pharma GmbH as lead sponsor.

NCT NCT01388621
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01388621 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PROVE A Randomized Phase II Trial of Standard Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer
Lead sponsor
WiSP Wissenschaftlicher Service Pharma GmbH
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2011
Completion date
July 31, 2015
Enrollment
140 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer